Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market

被引:15
|
作者
Shabaninejad, Hosein [1 ]
Mehralian, Gholamhossein [2 ,3 ]
Rashidian, Arash [4 ]
Baratimarnani, Ahmad [1 ]
Rasekh, Hamid Reza [2 ,3 ]
机构
[1] Iran Univ Med Sci, Sch Hlth Management & Informat Sci, Dept Hlth Serv Management, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Pharmacoecon & Pharma Management, Tehran, Iran
[3] Univ Tehran Med Sci, Sch Publ Hlth, Dept Hlth Management & Econ, Tehran, Iran
[4] Univ Tehran Med Sci, Knowledge Utilizat Res Ctr, Dept Hlth Management & Econ, Tehran, Iran
关键词
Competitiveness; Pharmaceutical industry; Key factors; Human capital; Iran; RESEARCH-AND-DEVELOPMENT; TECHNOLOGICAL-INNOVATION; TOPSIS; ADVANTAGE; ISSUES; RETURN;
D O I
10.1186/2008-2231-22-35
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Background: Pharmaceutical industry is knowledge-intensive and highly globalized, in both developed and developing countries. On the other hand, if companies want to survive, they should be able to compete well in both domestic and international markets. The main purpose of this paper is therefore to develop and prioritize key factors affecting companies' competitiveness in pharmaceutical industry. Based on an extensive literature review, a valid and reliable questionnaire was designed, which was later filled up by participants from the industry. To prioritize the key factors, we used the Technique for Order Preference by Similarity to Ideal Solution (TOPSIS). Results: The results revealed that human capital and macro-level policies were two key factors placed at the highest rank in respect of their effects on the competitiveness considering the industry-level in pharmaceutical area. Conclusion: This study provides fundamental evidence for policymakers and managers in pharma context to enable them formulating better polices to be proactively competitive and responsive to the markets' needs.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Identifying and prioritizing industry-level competitiveness factors: evidence from pharmaceutical market
    Hosein Shabaninejad
    Gholamhossein Mehralian
    Arash Rashidian
    Ahmad Baratimarnani
    Hamid Reza Rasekh
    [J]. DARU Journal of Pharmaceutical Sciences, 22
  • [2] Inequality and growth: industry-level evidence
    Erman, Lisardo
    te Kaat, Daniel Marcel
    [J]. JOURNAL OF ECONOMIC GROWTH, 2019, 24 (03) : 283 - 308
  • [3] Inequality and growth: industry-level evidence
    Lisardo Erman
    Daniel Marcel te Kaat
    [J]. Journal of Economic Growth, 2019, 24 : 283 - 308
  • [4] The costs of tax havens: evidence from industry-level data
    Jansky, Petr
    [J]. APPLIED ECONOMICS, 2020, 52 (29) : 3204 - 3218
  • [5] Does Global Value Chain Integration Enhance Export Competitiveness? Evidence from Indonesia's Industry-Level Analysis
    Jangam, Bhushan Praveen
    Rath, Badri Narayan
    Ridhwan, Masagus M.
    [J]. EMERGING MARKETS FINANCE AND TRADE, 2024, 60 (07) : 1578 - 1598
  • [6] Sudden stops and financial frictions: Evidence from industry-level data
    Cowan, Kevin
    Raddatz, Claudio
    [J]. JOURNAL OF INTERNATIONAL MONEY AND FINANCE, 2013, 32 : 99 - 128
  • [7] Fixed Broadband and Economic Growth: Industry-Level Evidence from the OECD
    Fretz, Stephan
    [J]. ECONOMICS OF INFRASTRUCTURE PROVISIONING: THE CHANGING ROLE OF THE STATE, 2015, : 427 - 448
  • [8] Corporate environmentalism and international trade: Evidence from industry-level data
    Sam, Abdoul G.
    Song, Danbee
    [J]. CORPORATE SOCIAL RESPONSIBILITY AND ENVIRONMENTAL MANAGEMENT, 2022, 29 (05) : 1440 - 1455
  • [9] Domestic market competitiveness of Indian drug and pharmaceutical industry
    Varun Mahajan
    D. K. Nauriyal
    S. P. Singh
    [J]. Review of Managerial Science, 2020, 14 : 519 - 559
  • [10] Industry-Level Competitiveness, Productivity and Effective Exchange Rates in East Asia
    Ito, Keiko
    Shimizu, Junko
    [J]. ASIAN ECONOMIC JOURNAL, 2015, 29 (02) : 181 - 214